106331-89-9

Upstream product

• 5438-36-8 5-iodovaniline 
• 107-08-4 1-iodo-propane 
• 540-54-5 1-Chloropropane 
• 106-94-5 propyl bromide 

Downstream Products

• 133095-92-8 4-(3-Iodo-5-methoxy-4-propoxy-phenyl)-4-oxo-butyric acid tert-butyl ester 
• 145399-74-2 3-methoxy-4-propoxy-5-iodobenzoic acid 
• 127974-65-6 5--1-iodo-3-methoxy-2-propoxybenzene 
• 135947-75-0 MK 287 
• 140705-14-2 (2S,5S)-2-(3',4',5'-trimethoxyphenyl)-5-[3-methoxy-5-(2'-t-butyldimethylsilyloxyethanesulfonyl)-4-propoxyphenyl]tetrahydrofuran 
• 481725-12-6 1-bromo-3-methoxy-4-propoxy-5-iodobenzene 
• 481725-13-7 1-bromo-3-methoxy-4-propoxy-5-(2'-hydroxyethanesulfanyl)benzene 
• 481725-11-5 1-bromo-3-methoxy-4-propoxy-5-(2'-tert-butyldimethylsilyloxyethanesulfanyl)benzene 
• 481725-19-3 (2S,5S)-2-(3',4',5'-trimethoxyphenyl)-5-[3-methoxy-5-(2'-t-butyldimethylsilyloxyethanesulfanyl)-4-propoxyphenyl]-2,5-dihydrofuran 
• 481725-20-6 (2S,5S)-2-(3',4',5'-trimethoxyphenyl)-5-[3-methoxy-5-(2'-t-butyldimethylsilyloxyethanesulfanyl)-4-propoxyphenyl]tetrahydrofuran 
• 481725-18-2 (1R,2S,3S,5S,6R,7S)-4,10-dioxa-3-[3-methoxy-5-(2'-t-butyldimethylsilyloxyethanesulfanyl)-4-propoxy]-5-[(3',4',5')-trimethoxyphenyl]-tricyclo[5.2.1.0^2,6]dec-8-ene 
• 481725-17-1 (1R,2S,3S,5S,6R,7S)-4,10-dioxa-3-[3-methoxy-5-(2'-t-butyldimethylsilyloxyethanesulfanyl)-4-propoxy]-5-[(3',4',5')-trimethoxyphenyl]-tricyclo[5.2.1.0^2,6]dec-8-en-3-ol 
• 106331-90-2 1-(5-iodo-3-methoxy-4-n-propoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-1,4-butanedione 
• 127974-74-7 (+)-(2S,3S,4R)-2-(Benzyloxy)-4-(4-fluorobenzoyl)-3-<(3-iodo-5-methoxy-4-propoxyphenyl)bis(phenylthio)methyl>tetrahydrofuran 

Relevant academic research and scientific papers

Newly designed and synthesized curcumin analogs with in vitro cytotoxicity and tubulin polymerization activity

Novel curcumin analogs with 4-piperidone ring were designed, synthesized, and evaluated for their cytotoxic activities against five different cancer cell lines. 3,5-bis(4-Hydroxy-3-methoxybenzylidene)-4-oxo-N-phenylpiperidine-1-carbothioamide (XIIe) exhib

Enantioselective synthesis of the PAF antagonist MK-287

Following a general method of synthesis of optically active 2,5-disubstituted tetrahydrofurans, an enantioselective synthesis of the PAF antagonist, MK-287 is described.

COMPOUNDS AND METHODS FOR THE TREATMENT OF DISORDERS MEDIATED BY PLATELET ACTIVATING FACTOR OR PRODUCTS OF 5-LIPOXYGENASE

2,5-Diaryl tetrahydrofurans, 2,5-diaryl terahydrothiophenes, 2, 4-diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiphenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i.e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. A method to treat disorders mediated by PAF or leukotrienes is also disclosed, that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

Conversion of a silylated hemiacetal into an α-bromoether using trimethylsilylbromide. Synthesis of platelet activating factor antagonist L-659,989

An efficient synthesis of platelet activating factor antagonist L-659,989 has been achieved in ten steps from commercially available 5-iodovanillin. The key transformation converts a silylated hemi-acetal into an α-bromoether followed by a highly stereose